Dechra Pharmaceuticals buys Caledonian for NZD8.7m
8th Oct 2018 07:24
(Sharecast News) - Specialist veterinary pharmaceuticals group Dechra Pharmaceuticals announced the acquisition of Caledonian for NZD8.7m (£4.4m).
Read moreJefferies repeats 'buy' rating on Dechra after results tumble
3rd Sep 2018 11:09
(Sharecast News) - Although investors were unimpressed with Dechra's annual results and sent the shares galloping down, analysts at Jefferies liked the "impressive growth" in North America during the veterinary products manufacturer's last trading year.
Read moreDechra dives despite solid profits growth
3rd Sep 2018 07:26
(Sharecast News) - Veterinary pharmaceutical business Dechra Pharmaceuticals issued a solid set of preliminary results on Monday, but a warning about the fast past of change in the industry saw many investors take profits.
Read moreDechra revenue surges after several acquisitions
17th Jan 2017 07:40
(ShareCast News) - As a result of several acquisitions veterinary pharmaceutical Dechra's half year revenue surged, while it gained regulatory approval in the US for its generic antibiotic. Revenue for the six months ended 31 December 2016 jumped 34% at a constant exchange rate, or 56% at actual rat
Read moreDechra Pharmaceuticals says Q1 performance in line
21st Oct 2016 10:54
(ShareCast News) - Dechra Pharmaceuticals said its first-quarter performance was in line with management's views and that all of its recent acquisitions were performing well. The company also confirmed the retirement of chairman Michael Redmond after its AGM on Friday, with successor Tony Rice there
Read moreDechra buys Apex Lab for AUD$55m
16th Sep 2016 07:10
(ShareCast News) - Veterinary product manufacturer Dechra Pharmaceuticals agreed to buy the business and assets of Apex Laboratories, which sells branded animal products in Australia and New Zealand, for AUD$55m (£31.3m). The acquisition, to be finalised on 14 October, will be funded from cash and d
Read moreFDA approves Dechra Pharma's generic antibiotic
9th Sep 2016 07:42
(ShareCast News) - Dechra Pharmaceuticals obtained its first approval for a product from its recently acquired US business Putney. The drug firm hailed the approval of its generic antibiotic by the US Food and Drug Administration, seeing it as confirmation of the capabilities of its specialist pharm
Read moreDechra Pharmaceuticals revenue up following acquisitions
5th Sep 2016 07:31
(ShareCast News) - Dechra Pharmaceuticals reported a jump in underlying profit for the year as revenue grew following a number of acquisitions. In its preliminary results for the year ended 30 June, the veterinary pharmaceutical business said underlying operating profit came in at £52.9m from £44.4
Read moreDechra Pharmaceuticals full-year revenue up 21%
12th Jul 2016 07:40
(ShareCast News) - Veterinary products manufacturer Dechra Pharmaceuticals said on Tuesday that full-year trading was strong and expressed confidence that it would not be hit by recent market volatility. The company saw revenue growth of 21% at constant exchange rates. Excluding acquisitions, revenu
Read moreDechra to gobble up Putney in £140m deal
15th Mar 2016 08:05
(ShareCast News) - Veterinary group Dechra Pharmaceuticals looked set to expand its reach in the US market on Tuesday, announcing the conditional acquisition of Maine-based generic pet pharmaceutical developer Putney. At the same time, the FTSE 250 firm announced it had placed 4,398,600 new ordinary
Read moreFTSE 250 movers: Home Retail leads risers over possible bidding war
22nd Feb 2016 15:29
(ShareCast News) - The FTSE 250 was firmly in the black on Monday, up 124.90 points (0.77%) to 16,282.96 by mid-afternoon. Home Retail Group led the risers following media reports over the weekend that Sainsbury's could seek an extension to the Takeover Panel's 18 March deadline, after South African
Read moreMonday broker round-up
22nd Feb 2016 13:49
(ShareCast News) - Coca-Cola Hbc: JP Morgan reiterates neutral with a target price of 1450p, Nomura stays at buy with a 1330p target and Deutsche Bank keeps at hold with a target price of 1500p. Standard Life: JP Morgan keeps at overweight with a target of 465p and Deutsche Bank reiterates buy, 415p
Read moreExchange rate headwinds prevail at Dechra
22nd Feb 2016 07:46
(ShareCast News) - Exchange rates were proving a headwind for Dechra Pharmaceuticals, with the firm reporting good revenue growth in its first half to 31 December, muted by the cost of conversion. The FTSE 250 company said trading in the first half was strong, with group revenue growth - including G
Read moreBroker tips: Home Retail, Dechra Pharma, StanChar
14th Jan 2016 14:06
(ShareCast News) - Dechra Pharmaceuticals remains a strong stock with plenty in the pipeline, according to Investec on Thursday. In a trading update for the first half, the company reported revenue growth of 15% at a constant exchange rate (CER), including the integration of Genera which was bought
Read moreDechra Pharmaceuticals a strong stock, says Investec
14th Jan 2016 10:42
(ShareCast News) - Dechra Pharmaceuticals remains a strong stock with plenty in the pipeline, according to Investec on Thursday. In a trading update for the first half, the company reported revenue growth of 15% at a constant exchange rate (CER), including the integration of Genera which was bought
Read more